The DNA strand break-binding molecule, poly(ADPribose) polymerase-1 (PARP-1), plays a role in DNA repair, chromosomal stability, transcription and cell death. Accumulating evidence suggests that dysfunction of PARP-1 contributes to tumorigenesis. Here, we report that PARP-1 deficiency causes mammary carcinoma formation in female mice, and that the introduction of Trp53 mutations accelerates the onset and shortens the latency of mammary tumorigenesis. We show that PARP-1 deficiency results in chromosomal aneuploidy and centrosome amplification, which are substantiated by the inactivation of Trp53 in primary mammary epithelial (PME) cells. In addition, PARP-1 deficiency compromises p53 activation and impairs BRCA1 recruitment to the sites of DNA damage in PME cells. PARP-1 complementation partly rescues the defective DNA damage response mediated by p53 and BRCA1. The present study thus identifies a role of PARP-1 in suppressing mammary tumorigenesis in vivo and suggests that dysfunction of PARP-1 may be a risk factor for breast cancer in humans.
Introduction
Poly(ADP-ribose) polymerase-1 (PARP-1), a member of the PARP superfamily, is a DNA strand break-sensing protein, and its activation is one of the early responses to DNA damage (Ame et al., 2004) . PARP-1 catalyses poly ADP-ribosylation, an immediate DNA-damagedependent post-translational modification of histones and other nuclear proteins, and may play a multifunctional role in various cellular processes, including DNA damage detection and repair, chromatin modification, transcription, cell death pathways, insulator function and mitotic apparatus function. These processes indicate a critical role of PARP-1 for many physiological and pathophysiological outcomes, including genome maintenance, carcinogenesis, aging, inflammation and neuronal function (reviewed in Kim et al., 2005) .
Genomic instability is a hallmark of tumorigenesis (Hanahan and Weinberg, 2000) . Recent studies using PARP-1 mutant mice have implicated PARP-1 in the suppression of tumorigenesis (Tong et al., 2001a; Masutani et al., 2003) . Although PARP-1À/À mice develop spontaneous tumors at a low incidence (Tong et al., 2002) , they are susceptible to chemical carcinogeninduced tumorigenesis, with increased mutation rates (Tsutsumi et al., 2001; Nozaki et al., 2003; Shibata et al., 2005) . Inactivation of PARP-1 has been shown to result in a high frequency of T-cell lymphomas in severe combined immunodeficiency mice (Morrison et al., 1997) . In addition, PARP-1 deficiency provoked the formation of various epithelial and neuronal tumor, and shortened the latency of lymphoma in Trp53 mutant mice (Beneke and Moroy, 2001; Tong et al., 2001b Tong et al., , 2003 . Moreover, haploinsufficiency of non-homologous end-joining molecule Ku80 promoted hepatocellular carcinomas in PARP-1-deficient mice (Tong et al., 2002) , and PARP-1 cooperated with Werner syndrome protein in the maintenance of chromosomal integrity and in suppressing tumorigenesis (Lebel et al., 2003) .
Breast cancer is one of the most common malignancies, with more than one million cases occurring worldwide annually, and is the second-leading cause of cancer mortality affecting women (Stewart and Kleihues, 2003) . Mutations in the breast cancer susceptibility genes BRCA1 and BRCA2, which are involved in DNA double strand break (DSB) repair and homologous recombination, are associated with highpenetrance human hereditary breast cancer, and account for 5-9% of all breast cancers (Venkitaraman, 2002) . In addition, mutations in tumor suppressor gene Trp53 are frequently found in sporadic breast cancers. LiFraumeni syndrome with germline mutations of Trp53 and checkpoint kinase 2 gene Chk2 are known to increase breast cancer risk (Malkin, 1998; Bell et al., 1999) . Furthermore, familial human BRCA1 or BRCA2 cancer cases frequently contain Trp53 mutations (Crook et al., 1997) .
It has been shown that inactivation of BRCA1 or BRCA2, specifically in mouse mammary glands, causes breast cancer with long latency (Cressman et al., 1999; Xu et al., 1999; Jonkers et al., 2001; Ludwig et al., 2001) , suggesting that additional genetic events are required to fulfill malignant transformation. Combined mutations of BRCA1 or BRCA2 with Trp53 in mice resulted in a significant increase of mammary carcinogenesis (Cressman et al., 1999; Xu et al., 1999; Jonkers et al., 2001) , indicating that defects in DNA repair with a compromised cell cycle checkpoint function play a fundamental role in breast tumorigenesis.
In the present study, we report that PARP-1 deficiency causes mammary carcinomas in mice, and additional Trp53 mutations accelerate the onset and shorten the latency of mammary tumorigenesis. In addition, we have characterized early genetic and molecular alterations in PARP-1-deficient mammary epithelial cells and shown that PARP-1 is essential in regulating BRCA1 in response to DNA damage.
Results

PARP-1 deficiency causes mammary carcinomas in mice
We have previously shown that PARP-1 deficiency causes a high incidence of epithelial tumors in Trp53 heterozygous mice, including mammary carcinomas (Tong et al., 2001b) . To further explore whether PARP-1 deficiency alone plays a role in mammary tumorigenesis, we intercrossed PARP-1À/À and PARP-1 þ / þ mice, respectively, for seven subsequent generations in a 129/Sv Â C57BL/6 background. A large cohort of these mice from the fourth to seventh generation (designated as G4-G7) was monitored for tumor development. To examine the mammary glands in detail, each fourth pair of mammary glands was subjected to whole-mount staining and subsequent histological examination at the age of 20-24 months. No mammary lesions were found in 45 PARP-1 þ / þ glands from G4 to G7 females ( Figure 1a) . However, the morphological alterations of mammary duct, nodular lesions (Figure 1b and c) were evident in 46 PARP-1À/À aged females analysed.
Histological analysis of these lesions confirmed mammary ductal hyperplasia ( Figure 1e ) and tumor ( Figure 1f ). Immunostaining of E-cadherin and pancytokeratin on these tumors revealed various levels of expression ( Figure 1g , data not shown), indicative of their epithelial origin. In addition, a high frequency of proliferation marker Ki67 staining was observed in these carcinoma cells (Figure 1h ). Moreover, disruption of the myoepithelial layer of the mammary duct characterized by a-smooth muscle actin (SMA) immunostaining suggested an invasive character of PARP-1-deficient mammary carcinomas (Figure 1i ). Altogether, PARP-1 deficiency caused mammary carcinomas in four of 22 (18%) from G4 to G5 and five of 24 (21%) from G6 to G7 aging females (Figure 1j ).
Trp53 heterozygosity accelerates mammary carcinogenesis in PARP-1-deficient mice Trp53 mutations are associated with breast carcinogenesis in mice (Xu et al., 1999) . To test whether functional alteration of Trp53 represents one of the genetic factors for PARP-1 deficiency-induced mammary carcinomas, we deleted one allele of Trp53 in PARP-1-deficient mice. Of 35 PARP-1 þ /À;Trp53 þ /À and 32 PARP-1À/À;Trp53 þ /À females monitored over 24 months, eight (23%) PARP-1 þ /À;Trp53 þ /À and 11 (34%) PARP-1À/À;Trp53 þ /À females developed mammary carcinomas, respectively (Figure 1j ). Compared with the carcinoma onset of PARP-1À/À mice, Trp53 heterozygosity accelerates the mammary carcinogenesis in both PARP-1 þ /À and PARP-1À/À mice. Moreover, mammary carcinomas can be detected as early as 10 months of age in PARP-1À/À;Trp53 þ /À females ( Figure 1j ).
Trp53 null allele induces mammary epithelial hyperplasia and carcinomas in PARP-1À/À females at an early age To further study the impact of Trp53-null allele on mammary carcinogenesis in PARP-1À/À mice, the fourth pair of mammary glands from 20 PARP-1À/À; Trp53À/À females were isolated between 3 and 6 months when the mice were killed because of an early onset of lymphoma and brain tumors . Notably, whole-mount mammary gland examination revealed profound morphological alterations in all PARP-1À/À;Trp53À/À females, including sparse ductal branching, local and diffused ductal hyperplasia and ectasia (Figure 2b-d) . Subsequent histological analysis of the mammary glands revealed mammary ductal epithelial hyperplasia and dysplasia associated with severe stromal reaction (Figure 2g -i) and neovascularization (Figure 2h) . Notably, two mice (10%) developed mammary carcinomas at 5 months of age (Figures 1j and 2j) . However, no mammary lesions were observed in age-matched (Figure 2a and e-f and data not shown).
PARP-1;Trp53-deficient mammary carcinomas and loss of heterozygosity Histopathological analysis revealed that mammary carcinomas arising from PARP-1À/À;Trp53 þ / þ and PARP-1-deficient Trp53 þ /À females included cribriform carcinoma (Figure 3a ), papillary carcinoma ( Figure 3b ) and solid carcinoma ( Figure 3c ). Individual tumors frequently consisted of more than two tumor types, such as the cribriform with solid carcinomas (Figure 3d ), papillary with glandular carcinomas, rarely adenosquamous carcinoma and adeno-epithelioma (not shown). In addition, mammary epithelial lesions were often accompanied by reactive stromas and neovascularization ( Figure 3e ). Local lympho-vascular invasion of tumor cells was also observed in three females ( Figure 3f ).
The early onset of mammary carcinomas in PARP-1À/À;Trp53 þ /À mice compared to that in PARP-1À/À mice suggested a genetic synergy between PARP-1 and p53 in mammary carcinoma development. Trp53 heterozygote mice develop spontaneous tumors in late life, which is associated with loss of the wild-type Trp53 allele (Donehower et al., 1992) . To investigate whether early onset of mammary carcinomas in PARP-1-deficient Trp53 heterozygote mice is due to PARP-1 deficiency promoting the loss of functional p53, we performed polymerase chain reaction (PCR) analysis for the wild-type Trp53 allele derived from PARP-1À/ À;Trp53 þ /À mammary carcinomas. We analysed six tumors and found that all of them showed loss or partial loss of the wild-type Trp53 allele (Figure 3g ). The remaining wild-type Trp53 could be possibly the contamination of stromal cells in mammary tissues. Indeed, primary mammary carcinomas cells (PC) isolated from these tumors showed complete loss of the wild-type Trp53 allele (Figure 3g ).
PARP-1 deficiency causes aneuploidy in primary mammary epithelial cells
To understand the early molecular and genetic events of PARP-1 deficiency-induced mammary carcinomas, we performed cytogenetic analyses of PARP-1-deficient primary mammary epithelial (PME) cells and monitored chromosomal aberrations (Figure 4a ). All wild-type PME cells were diploid and without chromosomal aberration, whereas 11% of PARP-1À/À PME cells were aneuploid (Figure 4a ). Trp53 þ /À or Trp53À/À dramatically increased the frequency of aneuploidy and chromosomal aberrations in PARP-1À/À PME cells (Figure 4a ). These cytogenetic changes in PARP-1 mutant PME cells are consistent with previous studies using primary and immortalized mouse embryonic fibroblasts (Tong et al., 2001b; Kanai et al., 2003) .
PARP-1 deficiency leads to centrosome amplification in PME cells Centrosome amplification is associated with mammalian breast cancers (Deng, 2002) . To evaluate whether the centrosome function is associated with chromosomal aberrations of PARP-1 and Trp53 mutant PME cells, we then performed centrosome immunostaining in these cells. Wild-type PME cells display one or two centrosomes according to cell proliferation stage (Figure 4b ). Although 3% of the PARP-1 þ / þ ;Trp53À/À PME cells studied contained more than two centrosomes, 6% of PARP-1À/À;Trp53 þ / þ PME cells contained abnormally amplified centrosomes (Figure 4b ). Trp53 mutations, either heterozygous or homozygous, substantially increased the proportion of PARP-1À/À PME cells containing amplified centrosomes (Figure 4b ). These results indicate that PARP-1 and p53 play a synergistic role in the maintenance of centrosome function and chromosomal stability in PME cells.
PARP-1 deficiency compromises p53 function upon DNA damage As p53 regulates cell cycle progression in response to DNA damage, we investigated whether chromosomal aberrations in PARP-1-deficient PME cells could activate p53. Although Western blotting analysis revealed a similar basal level of p53 phosphorylation at serine 18 (Ser-18, corresponding to Ser-15 of human p53, which is phosphorylated by ataxia-telangiectasia mutated (ATM) in response to ionizing radiation and UV; Chao et al., 2000) in PARP-1-proficient and -deficient PME cells (0 h, without adriamycin (Adr) treatment, Figure 5a ), the basal level of p21, a downstream effectors of p53 responsible for cell cycle arrest, was more than three to five-fold higher in PARP-1-deficient PME cells than in wild-type PME cells (Figure 5a ). Upon DNA damage induced by Adr, phosphorylation of p53 at Ser-18 in wild-type PME cells was significantly increased at 4 h and decreased to above the basal level at 12 h; consequently, activation of p21 protein was evident (Figure 5a ). Although phosphorylation of p53 at Ser-18 could occur in response to DNA damage, PARP-1 deficiency reduced level of phosphorylated p53, which was sustained until 12 h in PME cells (Figure 5a ). In addition, PARP-1 deficiency compromised activation of p21 (Figure 5a ).
To investigate whether compromised p53 function in response to DNA damage in PME cells was indeed caused by a lack of PARP-1 protein, we restored PARP-1 expression in a primary cultured PARP-1 null mammary carcinoma cells by transient transfection of the full-length human wild-type hPARP-1 cDNA for 48 h, and DNA damage was induced by Adr treatment. Primary mammary carcinoma cells complemented with Figure 4 Chromosomal and centrosome analyses. (a) Summary of metaphase chromosomes in PARP-1 and/or Trp53 mutant PME cells. *Chromosomal aberrations include fusions, breaks and fragments; number of chromosomal aberrations per metaphase is shown in parenthesis. (b) Summary of centrosome analysis in PARP-1 and/or Trp53 mutant PME cells. The number of centrosome/cell (i.e. 1, 2, or >2 centrosomes) was determined in PME cells of each genotype. For the analysis, at least 80 cells were examined randomly from two independent experiments, and 2-3 mice of each genotype were used for each culture.
hPARP-1 revealed an improved phosphorylation of p53 at Ser-18 and p21 activation compared to that in PARP-1-deficient controls (Figure 5b ). The role of PARP-1 in rescuing defects of p53 function in DNA damage response has also been further confirmed in a stable hPARP-1-transfected PARP-1 null epithelial cells (Supplementary Figure S1 ). Thus, PARP-1 is likely involved in an efficient activation of p53 signaling in response to DNA damage.
PARP-1 deficiency affects BRCA1 recruitment to sites of DNA damage BRCA1 is a mammary tumor suppressor that is rapidly phosphorylated by ATM upon DNA damage and is required for DNA DSB repair (Cortez et al., 1999; Li et al., 2000) . We sought to determine whether PARP-1 deficiency affects BRCA1 function by analysing its foci formation in response to DNA damage. When DSBs were induced, BRCA1 foci were detected in 50% of wild-type PME cells (Figure 6a-b) , but only in 22% of PARP-1-deficient PME cells, a statistically significant reduction (Po0.01; Figure 6a-b) . As histone H2Ax is rapidly phosphorylated at serine 139 (gH2Ax) to form foci in response to DSBs, and BRCA1 is an early migrant to sites of gH2Ax (Paull et al., 2000) , we also sought to determine whether the defects in BRCA1 recruitment to sites of DNA damage in PARP-1-deficient PME cells were caused by alteration of gH2Ax foci formation. Upon DNA damage, similar levels of gH2Ax foci were detected in wild-type and PARP-1-deficient PME cells (Figure 6c-d) , implying that PARP-1 deficiency does not affect gH2Ax foci formation.
To further test whether the defects of BRCA1 recruitment to sites of DNA damage in PARP-1-deficient PME cells might be a direct effect of PARP-1 deficiency, we analysed BRCA1 foci formation in PARP-1-deficient and stable hPARP-1-complemented epithelial cells (Supplementary Figure S1a) . In accordance with our observations in the PME cells ( Figure  6a-b) , upon DNA damage, about 25% of PARP-1-deficient cells were BRCA1 foci-positive (Figure 6e) . However, reintroduction of PARP-1 significantly increased BRCA1 foci-positive cells (Figure 6e ). g-H2Ax foci formation in both PARP-1-deficient and -complemented cells was induced at the same level in response to DNA damage (Figure 6f ). This result implies that PARP-1 protein is required for BRCA1 recruitment to sites of DNA breaks.
Discussion
In this report, we have provided compelling evidence that DNA strand break-sensing molecule PARP-1 is involved in mammary carcinogenesis in mice. We have shown that PARP-1-deficient mice developed lowincidence spontaneous mammary tumors with long latency and that introduction of Trp53 mutations significantly shortens mammary tumor latency and increases tumor incidence in PARP-1-deficient mice.
Although PARP-1 deficiency did not affect normal mammary gland development in virgin females, PARP-1;Trp53 double null mammary glands developed high frequency of preneoplastic lesions at an early age. Owing to an early lethality caused by lymphoma, sarcomas and brain tumors in these mice (Tong et al., 2001b , the incidence of mammary carcinomas in PARP-1;Trp53 double null mice may have been underestimated. The animal models to date suggest that PARP-1 may function as an additional etiological factor related to breast cancer in humans. Thus, in DNA repair deficiency-induced breast cancer, inactivation of the p53 pathway likely represents the most direct means to bypass the cellular surveillance system. This notion is in agreement with the finding that Trp53 mutation is most frequently observed in BRCA1/BRCA2-associated breast cancer in humans (Crook et al., 1997) and in mice (Cressman et al., 1999; Xu et al., 1999; Jonkers et al., 2001) .
We have used PME cells to address the early molecular and genetic events leading to tumorigenesis. We found that PARP-1 deficiency causes chromosomal aneuploidy and abnormal centrosome amplification in PME cells and inactivation of Trp53 cooperates with PARP-1 deficiency in these processes. These findings are consistent with previous studies using primary mouse fibroblasts (Tong et al., 2001b; Kanai et al., 2003) . Although deletion of PARP-1 did not affect DNA damage recognition through phosphorylation signaling, namely gH2Ax foci formations, recruitment of BRCA1 to sites of DNA damage and phosphorylation of p53 at Ser-18 were compromised in PME cells. Interestingly, these defects can be partly restored by hPARP-1 complementation. Thus, these results suggest that PARP-1 regulates BRCA1 function in response to DNA damage. Taken together, chromosomal aberrations, abnormal centrosome amplification and compromised p53 and BRCA1 function in PARP-1-deficient mammary epithelial cells may generate a strong selective pressure for those cells to have a growth advantage resulting in hyperplasia, with additional genetic and cellular alterations leading to mammary tumorigenesis.
Interestingly, inhibition of PARP-1 leads to specific killing of cells impaired in BRCA1 or BRCA2 function (Helleday et al., 2005) , although the specificity becomes less significant when breast cancer cells are tested (De Soto and Deng, 2006; . PARP-1 inhibition resulted in persistent single-strand breaks, defects in DSB repair involving RAD51-dependent homologous recombination, collapse of replication forks in BRCA1 or BRCA2 mutant cells and accumulation of chromosomal abnormalities, as well as cell cycle arrest in G2/M, leading to apoptosis Farmer et al. 2005; McCabe et al., 2005) . These studies suggest a potential role for PARP-1 inhibitors in therapy for cancers involving BRCA1 or BRCA2 deficiency. However, our in vivo data suggest that long-term inhibition of PARP-1 activity may bring increased risk for breast cancer formation.
In summary, the present study reveals an important role of PARP-1 in suppressing mammary tumorigenesis in mice. Although PARP-1 mutations have not been documented in human breast cancers, alterations of chromosome 1q41-42, where the PARP-1 is located, have been observed in a subset of human breast cancer (Bieche et al., 1996) . In addition, recent epidemiological studies showed that a single nucleotide polymorphism of PARP-1 (Val762Ala) was associated with human prostate, esophageal and lung carcinomas (Hao et al., 2004; Lockett et al., 2004; Zhang et al., 2005) . Moreover, downregulation of the PARP-1 activity has been observed in peripheral mononuclear leukocytes of breast (Hu et al., 1997) , head and neck (Rajaee-Behbahani et al., 2002) and prostate cancer patients (Lockett et al., 2004) , suggesting that genetic variants and alteration of PARP-1 enzymatic activity may contribute to human carcinogenesis (Shiokawa et al., 2005) . In this report, we have provided compelling in vivo evidence that PARP-1 deficiency causes mouse mammary carcinomas. Thus, further mutational or genetic variant analysis of the PARP-1 gene is required in understanding the impact of PARP-1 on human breast carcinogenesis.
Materials and Methods
Animal breeding scheme PARP-1 þ /À mice (129/Sv Â C57BL/6, Wang et al., 1995) were used to generate PARP-1 þ / þ and PARP-1À/À mice (generation 1, designated as G1), which were intercrossed respectively to obtain subsequent G2-G7 PARP-1 þ / þ controls and PARP-1À/À mice. Generation of PARP-1; Trp53 double-mutant mice (129/Sv Â C57BL/6) and genotyping for PARP-1 and Trp53 loci were performed as previously described (Tong et al., 2001b) . All animal experiments were approved by, and performed in accordance with the guidelines of the International Agency for Research on Cancer's Animal Care and Use Committee.
Mammary glands whole-mount and histolopathological analyses Animals were euthanized by deep anesthesia and the wholemount inguinal (fourth pair) mammary glands were dissected and fixed in methacarn, stained with Mayer's hematoxylin and cleared by immersing in methyl salicylate (Sigma, Steinheim, Germany). Whole-mount mammary glands and mammary carcinoma sections of 3 mm thickness were stained with hematoxylin and eosin (H&E). Immunohistochemical staining was performed as described previously (Tong et al., 2001b) . Primary antibodies were E-cadherin (Zymed, San Francisco, CA, USA), Ki67 (NovoCastra, Newcastle upon Tyne, UK) and a-SMA (Sigma). Biotinylated secondary antibodies (Elite Kit, Vector Laboratory, Burlingame, CA, USA) were used at a dilution of 1:1000. Visualization of antibody staining was achieved using an avidin/biotin peroxidase (Vector Laboratory) and diaminobenzidine as a chromogen. Tissue structures were visualized by counterstaining with Mayer's hematoxylin. Mammary carcinomas were classified based on the consensus report on the murine mammary cancer (Cardiff et al., 2000) .
LOH analysis of mammary tumors
For loss of heterozygosity (LOH) analysis, the Trp53 primers used in the PCR reactions were: X7 (5 0 -TAT ACT CAG AGC CGG CCT-3 0 ), NEO19 (5 0 -CAT TCA GGA CAT AGC GTT GG-3 0 ) and X6.5. (5 0 -ACA GCG TGG TGG TAC CTT AT-3 0 ). The PCR products for wild-type (X7-X6.5, 400 bp) and mutant Trp53 (X7-NEO19, 600 bp) were amplified with 35 PCR cycles (30 s at 941C; 45 s at 551C; 2 min 30 s at 651C). LOH determinations were based on the quantification of the ratio of wild-type and mutant band as described previously (Tong et al., 2001b) .
Cell cultures PME cells were isolated from wild-type, PARP-1À/À; Trp53 þ / þ , PARP-1 þ / þ ;Trp53À/À, PARP-1À/À;Trp53 þ /À and PARP-1À/À;Trp53À/À of 8-10-week-old virgin females as described previously (Edwards et al., 1996) . Short-term cultures were maintained with Dulbecco's modified Eagle's medium/F12 medium (Gibco, Paisley, UK) supplemented with 5 mg/ml insulin (Sigma), 5 mg/ml hydrocortisone (Sigma), 10 ng/ml epidermal growth factor (Sigma) and 5 ng/ml cholera toxin (Sigma). Primary mammary carcinoma cells were cultured as described (Tong et al., 2002) , and transiently transfected using PSG9 expression vector containing wild-type hPARP-1 cDNA (Herceg and Wang, 1999) or with an empty control vector by using a Lipofectamine transfection kit according to the instructions of the manufacturer (Invitrogen, Carlsbad, CA, USA) for 48 h. For DNA damage response studies, wild type and PARP-1À/À PME cells pooled from two to three mice of each culture were treated with 0.2 mg/ml Adr for 3 h and collected at indicated time points. Three independent experiments were performed. For cytogenetic analysis, metaphase spreads of PME cells were prepared following standard procedures, stained with a Cy-3-labeled telomeric probe ((CCCTAA)3 peptide nucleic acid) and counterstained by 4 0 ,6-diamidino-2-phenylindole (DAPI) and chromosomal aberrations were scored as described previously (Tong et al., 2001b) Indirect immunofluorescence Cells were grown on coverslips. The centrosome staining was performed as described previously (Kanai et al., 2003) . For g-H2Ax and BRCA1 foci staining, cells were treated with a hypotonic lysis solution containing 10 mM Tris-HCl pH7.4, 2.5 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.5% Nonidet P-40 for 8 min on ice and fixed in ice-cold acetone-methanol for 30 min on ice. Primary antibodies were monoclonal mouse anti-g-tubulin (Sigma), polyclonal rabbit antipericentrin (Covance, Berkeley, CA, USA), polyclonal rabbit anti-g-H2Ax (Upstate, Lake Placid, NY, USA), rabbit polyclonal BRCA1-1059 (Turner et al., 2004) . The antibodyantigen complexes were detected with fluoroscein isothiocyanate-conjugated antirabbit immunoglobulin (Ig)G and tetramethyl rhodamine isothiocynate-conjugated antimouse IgG antibodies (Dako, Carpinteria, CA, USA) by incubation for 1 h at 251C. The samples were counterstained with DAPI.
Western blot analysis Cells were homogenized in radioimmunoprecipitation assay buffer (50 mM Tris, pH7.4, 250 mM NaCl, 0.1% sodium dodecyl sulfate, 2 mM dithiothreitol, 0.5% NP40 and 500 mM PMSF, 2 mg/ml Aprotinin, 0.5 mg/ml Leupeptin, 2 mM Pepstatin). We resolved 40 mg of protein lysates by electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and blotted gel to the nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Antibodies were anti-p53 (CM5, NovoCastra), phosphorylated p53 Ser-15 (Cell Signaling, Beverly, MA, USA), p21 and PARP-1 (Pharmigen, San Diego, CA, USA). Proteins were visualized with horseradish peroxidase-conjugated goat antirabbit or antimouse IgG (Sigma) followed by the ECL chemiluminescence system (Amersham, Buckinghamshire, UK). We used mouse antiactin antibody (ICN Biomedicals, Irvine, CA, USA) to control protein loading.
Statistical analysis
Statistical analysis was performed using Sigma plot software.
